Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan.
Clin Chem Lab Med. 2010 Apr;48(4):505-12. doi: 10.1515/CCLM.2010.095.
Recent advanced techniques in glycobiology have produced a number of tumor marker candidates. As a result from the glycomic approach, we found that fucosylated haptoglobin in sera was a possible tumor marker for pancreatic cancer (PC). Although Aleuria aurantia lectin (AAL) blotting can detect fucosylated haptoglobin, it is difficult to quantify fucosylated haptoglobin precisely. To overcome this problem, we developed a fucosylated haptoglobin detection kit as a sandwich enzyme-linked immune sorbent assay (ELISA) using AAL and the Fab portion of anti-haptoglobin antibody. In the present study, we investigated the clinical application of this lectin-antibody ELISA kit to measure fucosylated haptoglobin in PC.
We measured fucosylated haptoglobin in patients with PC with a lectin-antibody ELISA kit. The fucosylated haptoglobin measured with this assay was compared with lectin blotting data, and the discrepancy was analyzed by immunoprecipitation methods. The concentration of fucosylated haptoglobin was investigated with respect to the clinical stage of PC. We also measured fucosylated haptoglobin, using 397 cases of several types of cancers including PC, benign diseases, and normal controls.
The sensitivity and specificity for the differential diagnosis of PC from normal controls was 50% and 91%, respectively. The results from lectin-antibody ELISA were significantly correlated with data from previous AAL blotting studies. Positive rates of fucosylated haptoglobin with this method in patients with PC were significantly higher in cases of stage IV compared with other clinical stages. Fucosylated haptoglobin was increased in several types of cancers, in which fucosylated haptoglobin was reported to increase.
While certain cases showed a discrepancy in fucosylated haptoglobin concentrations between the lectin-antibody ELISA and conventional lectin blotting, this novel type of lectin-antibody ELISA might be useful for a tumor marker for PC.
糖生物学的最新先进技术产生了许多肿瘤标志物候选物。通过糖组学方法，我们发现血清中岩藻糖化触珠蛋白可能是胰腺癌 (PC) 的肿瘤标志物。虽然 Aleuria aurantia 凝集素 (AAL) 印迹可以检测岩藻糖化触珠蛋白，但很难精确地定量岩藻糖化触珠蛋白。为了克服这个问题，我们开发了一种岩藻糖化触珠蛋白检测试剂盒，作为一种使用 AAL 和抗触珠蛋白抗体的 Fab 部分的夹心酶联免疫吸附测定 (ELISA)。在本研究中，我们研究了该凝集素-抗体 ELISA 试剂盒在测量 PC 中岩藻糖化触珠蛋白的临床应用。
我们使用凝集素-抗体 ELISA 试剂盒测量 PC 患者的岩藻糖化触珠蛋白。通过免疫沉淀方法分析了用该测定法测量的岩藻糖化触珠蛋白与凝集素印迹数据之间的差异。还根据 PC 的临床分期研究了岩藻糖化触珠蛋白的浓度。我们还使用 397 例包括 PC、良性疾病和正常对照在内的几种类型癌症的患者的样本测量了岩藻糖化触珠蛋白。
用于区分 PC 与正常对照的差异诊断的敏感性和特异性分别为 50%和 91%。凝集素-抗体 ELISA 的结果与之前的 AAL 印迹研究数据显著相关。与其他临床分期相比，该方法在 IV 期 PC 患者中岩藻糖化触珠蛋白的阳性率显著更高。在几种类型的癌症中，岩藻糖化触珠蛋白的浓度增加，在这些癌症中已经报道了岩藻糖化触珠蛋白的增加。
虽然在凝集素-抗体 ELISA 和传统凝集素印迹之间的岩藻糖化触珠蛋白浓度存在某些差异，但这种新型的凝集素-抗体 ELISA 可能对 PC 的肿瘤标志物有用。
